May 2007
BioWorld Today;5/11/2007, Vol. 18 Issue 92, p5
This section presents news briefs related to the biotechnology industry across the world. Atrium Biotechnologies Inc. in Quebec, changed its name to Atrium Innovations Inc. CytoGenix Inc. in Houston, Texas, and Eurogentec SA in Liege, Belgium, executed a letter of intent regarding the development of synDNA vaccine against human immunodeficiency virus. GenVec Inc. in Gaithersburg, Maryland, presented pre-clinical research demonstrating the ability of its new adenovector Ad35.


Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/5/2007, Vol. 18 Issue 66, p3 

    The article presents news briefs on biotechnology industry in the U.S. The holders of Chromos Molecular Systems Incorporated's convertible, secured bridge loan have demanded repayment of the principal and interest. CytoGenix Inc. has completed a pilot study for its synDNA vaccine for human...

  • Out to Sea.  // Cosmetics & Toiletries;Jan2007, Vol. 122 Issue 1, p92 

    The article features the Homeosta-Sea line of cosmetic ingredients from Atrium Biotechnologies Inc.

  • OTHER NEWS TO NOTE.  // BioWorld Today;10/22/2007, Vol. 18 Issue 205, p2 

    This section offers news briefs related to the biotechnology industry. Chromatin Inc. has granted to Syngenta Biotechnology Inc. nonexclusive rights to its gene-stacking technology for trait genes in corn and soybeans. The National Institute of Allergy and Infectious Diseases Vaccine Research...

  • OTHER NEWS TO NOTE.  // BioWorld Today;2/22/2010, Vol. 21 Issue 34, p3 

    This section offers news briefs in the biotechnology industry. A grant worth 1.2 million euros has been awarded by the Flemish agency for innovation by Science and Technology to Ablynx NV for preclinical and clinical development of the ALX-0061 drug for autoimmune and inflammatory diseases. The...

  • FINANCINGS ROUNDUP.  // BioWorld Today;8/28/2009, Vol. 20 Issue 166, p5 

    This section offers news briefs concerning finance of biotechnology companies. Avanir Pharmaceuticals Inc. obtained 10.6 million U.S. dollars by selling 4.5 million shares. A grant has been given to Clavis Pharma ASA, which could amount to 1.1 million U.S. dollars. A registered direct sale of...

  • VITAL SIGNS.  // BioWorld Today;2/12/2010, Vol. 21 Issue 29, p2 

    Charts are presented that list financings of private and public biotechnology companies in January 2010, which include Genvec Inc., Wex Pharmaceuticals and Cell Therapeutics.

  • Alliances/Collaborations. Holland-Moritz, Pam // Drug Discovery & Development;Feb2003, Vol. 6 Issue 2, p20 

    Reports on developments related to strategic alliances/collaborations in the pharmaceutical and biotechnology industries in the U.S. as of February 2003. Initial contract signed by GenVec Inc. with the U.S. Naval Medical Research Center for the use of GenVec's proprietary adenovector-based...

  • Other News To Note.  // BioWorld Today;8/9/2010, Vol. 21 Issue 152, p2 

    This section offers news briefs on the biotechnology industry. The board of Cypress Bioscience Inc. has rejected a proposal by shareholder Ramius LLC to acquire all of its outstanding shares for four U.S. dollars each in cash. A new supply agreement was signed by GenVec Inc. with Novartis AG to...

  • OTHER NEWS TO NOTE.  // BioWorld Today;7/30/2009, Vol. 20 Issue 145, p2 

    This section offers news briefs on the biotechnology industry as of July 30, 2009. Access Pharmaceuticals Inc. plans to evaluate strategic options for the commercialization of MuGard, a treatment for oral mucositis. Ambrilia Biopharma Inc. has laid off president and chief executive officer (CEO)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics